お知らせ • Jul 08
Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board
NewcelX Ltd. announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board. Dr. Ricordi is internationally recognized as one of the world's foremost authorities in diabetes cure-focused research, beta-cell replacement, and cellular transplantation. With more than 1,250 scientific publications, over 64,000 citations, an h-index of 123, and numerous pioneering contributions to the field of islet transplantation, Dr. Ricordi has played a central role in advancing cell-based approaches for type 1 diabetes worldwide. Dr. Ricordi currently serves as the Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant and NABTU Regenerative Medicine Center, and Director Emeritus of the Diabetes Research Institute (DRI). Since 1993, he has been the Professor of Surgery, Distinguished Professor of Medicine, and Professor of Biomedical Engineering, Microbiology and Immunology at the University of Miami Miller School of Medicine. He has also spent three decades as the Medical Director of the DRI cGMP Advanced Human Cell and Biologic Product Manufacturing Facility. He was the founding President of the Cell Transplant Society, President of the International Association for Pancreas and Islet Transplantation (IPITA), and served on the boards of The Transplantation Society and the American Society of Transplant Surgeons. He has also served on the FDA Biologic Response Modifiers Advisory Committee, several NIH study sections, and as an advisor or reviewer for international funding agencies. Dr. Ricordi invented the automated method (the Ricordi Chamber) for isolating large numbers of insulin-producing islet cells from the human pancreas - now the global standard for clinical islet transplantation - and performed the first series of successful clinical islet allotransplants to reverse diabetes. He chaired the steering committee of the first NIH-funded, FDA Phase 3 multicenter islet transplant trial, completed in 2017, and led the team that performed the first transplants of a bioengineered endocrine pancreas within a 3D resorbable scaffold. He has served as the Medical Director of the NIH-funded DRI cGMP Advanced Human Cell and Biologic Product Manufacturing Facility for three decades. He currently serves as Steering Committee Co-Chair and UM Principal Investigator for the Vertex stem cell–derived islet transplant program (VX-880) and is advancing a first-in-human trial with iTolerance of islet transplantation with a tolerance-inducing microgel, without chronic immunosuppression. Dr. Ricordi was the founding President of The Cure Alliance and Chairman of the Diabetes Research Institute Federation, coordinating and promoting cure-focused research among leading institutions worldwide. He was also the founding President of the Cell Transplant Society, President of the International Association for Pancreas and Islet Transplantation (IPITA), and served on the boards of The Transplantation Society and the American Society of Transplant Surgeons. His honors include the World Prize in Surgery (2001), the American Diabetes Association's Outstanding Scientific Achievement Award (2002), induction into the Association of American Physicians (2010) and the National Academy of Inventors (2018), and Knighthood from the President of Italy. He ranked as the world's leading expert in islet cell transplantation for the decade 2008–2018, according to Expertscape. Dr. Ricordi has authored over 1,250 publications cited more than 64,000 times (h-index 123) and holds 28 awarded patents. In 2023, he published The Healthspan Code, followed in 2025 by Therapeutic Revolution. Dr. Ricordi completed his medical degree at the University of Milan.